- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
FDA actions in brief, April 2008
Recent FDA approvals and indications (through April 2008) related to Xyntha, Simcor, Aloxl, Humira, Abilify, Avastin, Nexium, and Luvox.
Antihemophilic factor (recombinant), plasma/albumin-free (Xyntha, Wyeth) was approved for the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A.
A combination of niacin extended-release and simvastatin (Simcor, Abbott) was approved for use along with diet to lower levels of elevated total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, and to raise high-density lipoprotein (HDL) cholesterol levels in patients with complex lipid disease when treatment with simvastatin or niacin extended-release monotherapies are not considered adequate.
Palonosetron (Aloxi, Eisai) was approved for the prevention of postoperative nausea and vomiting for up to 24 hours after surgery.
Bevacizumab (Avastin, Genentech) was approved for use in combination with paclitaxel chemotherapy for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer.
Esomeprazole delayed-release capsules and an oral suspension (Nexium, AstraZeneca) were approved for short-term use in children aged 1 to 11 years for the treatment of gastroesophageal reflux disease (GERD).
An extended-release capsule formulation of fluvoxamine (Luvox CR, Jazz) was approved for the treatment of social anxiety disorder (SAD) and obsessive-compulsive disorder (OCD) in adults.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
